Document is current
Any future updates will be listed below
-
Authors
Mori, Takehiko https://orcid.org/0000-0002-8176-4760
Kikuchi, Taku
Yamazaki, Rie
Koda, Yuya
Saburi, Masuho
Sakurai, Masatoshi
Shigematsu, Naoyuki
Okamoto, Shinichiro
Kato, Jun
-
Funding
Funding for this research was provided by:
Pfizer Japan
NOVARTIS Foundation (Japan) for the Promotion of Science
- License Information
-
More Information
Article History
Received: 5 November 2020
Revised: 15 February 2021
Accepted: 18 February 2021
First Online: 1 March 2021
Declarations
:
: Takehiko Mori received research funding from MSD K. K., Novartis Pharma, LSI Medience, Medical and Biological Laboratories, Otsuka Pharmaceutical, Kyowa Kirin Co., Ltd., Shionogi and Co., Chugai Pharmaceutical, Takeda Pharmaceutical and Asahi Kasei Corporation, and personal fees from Pfizer Inc., MSD K. K., Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma K. K., Kyowa Kirin Co., Ltd., Chugai Pharmaceutical, Shionogi and Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Eisai Pharmaceuticals, and Astellas Pharma; Taku Kikuchi receives a personal fee from Bristol-Myers Squibb, Takeda Pharmaceutical, Otsuka Pharmaceutical, Eisai Pharmaceuticals, Sanofi K. K. and Janssen Pharma; Masuho Saburi receives a personal fee from Nippon Shinyaku Co., Ltd.; Masatoshi Sakurai receives research funding from Nippon Shinyaku Co., Ltd.; Shinichiro Okamoto receives research funding from Novartis Pharma K. K., Pfizer Inc., Sanofi K. K., Shionogi and Co., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma and Chugai Pharmaceutical, and personal fees from Nippon Shinyaku Co., Ltd. and Sanofi K. K.
